These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 35738455)

  • 1. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.
    Bendotti G; Montefusco L; Lunati ME; Usuelli V; Pastore I; Lazzaroni E; Assi E; Seelam AJ; El Essawy B; Jang J; Loretelli C; D'Addio F; Berra C; Ben Nasr M; Zuccotti G; Fiorina P
    Pharmacol Res; 2022 Aug; 182():106320. PubMed ID: 35738455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
    Abdelmalek MF; Harrison SA; Sanyal AJ
    Diabetes Obes Metab; 2024 Jun; 26(6):2001-2016. PubMed ID: 38511418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.
    Taha MB; Yahya T; Satish P; Laird R; Agatston AS; Cainzos-Achirica M; Patel KV; Nasir K
    Curr Atheroscler Rep; 2022 Aug; 24(8):643-654. PubMed ID: 35624390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
    Lovshin JA
    Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
    Ard J; Fitch A; Fruh S; Herman L
    Adv Ther; 2021 Jun; 38(6):2821-2839. PubMed ID: 33977495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
    Chun JH; Butts A
    JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
    Herrou J; Mabilleau G; Lecerf JM; Thomas T; Biver E; Paccou J
    Calcif Tissue Int; 2024 Feb; 114(2):86-97. PubMed ID: 37999750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1167-79. PubMed ID: 27563838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide agonists: A prospective review.
    Mariam Z; Niazi SK
    Endocrinol Diabetes Metab; 2024 Jan; 7(1):e462. PubMed ID: 38093651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
    Meece J
    Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications.
    Alharbi SH
    Ther Adv Endocrinol Metab; 2024; 15():20420188231222367. PubMed ID: 38288136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
    Brunton SA; Wysham CH
    Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
    Lim S; Kim KM; Nauck MA
    Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
    Barritt AS; Marshman E; Noureddin M
    Aliment Pharmacol Ther; 2022 Apr; 55(8):944-959. PubMed ID: 35266164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association.
    Cariou B
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S28-6S35. PubMed ID: 26774017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
    Patel Chavez C; Cusi K; Kadiyala S
    J Clin Endocrinol Metab; 2022 Jan; 107(1):29-38. PubMed ID: 34406410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons.
    Dalsgaard NB; Vilsbøll T; Knop FK
    Diabetes Obes Metab; 2018 Mar; 20(3):508-519. PubMed ID: 29024408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.